Status:
UNKNOWN
Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)
Lead Sponsor:
Rapid Laboratories Inc.
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a 24 week placebo controlled, double-blind, 2-arm study of ADAPTAVIR, Monomeric Dala1-peptide T-amide (mDAPTA) compared to placebo, in HIV infected individuals with suppressed plasma viral loa...
Detailed Description
A primary objective of this study is to assess the safety and toxicity of mDAPTA (Adaptavir) in HIV infected individuals with suppressed viral loads with HAART treatment and assess the proportion of s...
Eligibility Criteria
Inclusion
- HIV positive, male or female of any race and at least 18 years of age.
- Must have received continuous currently acceptable anti-retroviral therapy ("HAART"; highly active antiviral therapy) for at least six months prior to entry.
- Must have HIV-1 plasma viral load RNA (PCR or bDNA) \< 200 copies/mL for 90 days prior to randomization in this study.
- Women of childbearing potential must have a negative pregnancy test at screening prior to randomization in this study. Upon randomization, these women must agree to use methods of birth control or abstinence to prevent pregnancy.
- Must have a sustained CD4+ cell count \> 350 cells/mm3 for 90 days prior to randomization in this study.
- Must be considered clinically stable, in the opinion of the investigator, at the time of entry into the study.
Exclusion
- Expected to require adjustment to their antiretroviral therapy during screening or within 8 weeks after initiating mDAPTA therapy.
- Current participation in other clinical trials with investigational drugs.
- Use of any investigational agents including immunomodulatory agents (GM CSF, interferon, interleukin etc.) within 60 days prior to study entry.
- Use of any vaccine, including for Influenza (killed or live), Pneumovax etc., within 60 days of initiating therapy with mDAPTA.
- Use or anticipated use of immunosuppressive therapy, including chemotherapy during participation in the study.
- Alcohol or substance abuse which, in the opinion of the investigator, would interfere with patient compliance or safety.
- Study participants with an active opportunistic infection or malignancy.
- Pregnant or breastfeeding.
- Any condition or history of any illness which, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering the study drugs to the participant.
- Participants who previously received treatment with DAPTA.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00951743
Start Date
July 1 2009
End Date
July 1 2010
Last Update
August 11 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Whitman Walker Clinic
Washington D.C., District of Columbia, United States, 20009